
    
      This is a randomized placebo-controlled trial.

      The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide
      versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.
      This study is conducted under Special Protocol Assessment with the FDA and is designed to
      provide pivotal efficacy data on ecallantide. These data are intended to support the
      marketing authorization of ecallantide in the treatment of acute attacks of hereditary
      angioedema. Efficacy and safety of ecallantide will be evaluated in this study.
    
  